Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

The profitability screen requires that the sum of a company’s GAAP earnings over the past four quarters be positive as well as the most recent quarter. The screen imparts a slight quality tilt ...

MoA Aggressive Allocation Fund earns a High Process Pillar rating. The most important driver of the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight. At the Cardiometabolic Health Congress ...

Specializing in cutting-edge treatments like Semaglutide and Tirzepatide, Zest Meds has positioned itself as a leader in the weight loss industry. Their approach is simple yet effective ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

For example, a 2022 study of tirzepatide (the active ingredient in Mounjaro) prescribed for obesity included people with an average weight of 231 lb. After 18 months, participants on the lowest ...

“Obesity is a condition that affects more than 40% of our adult population and when factoring in candidacy for injections, such as those with overweight and a weight-related condition, the ...